ALLR News and Press, Allarity Therapeutics Inc. From 12/12/23

2023-12-12 06:09:27 ET More on Allarity Therapeutics Allarity stock soars 60% premarket on ovarian cancer therapy results Seeking Alpha’s Quant Rating on Allarity Therapeutics Historical earnings data for Allarity Therapeutics Financial information for...

Boston (December 12, 2023) — Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a clinical-stage pharmaceutical company developing novel oncology therapeutics together with drug-specific DRP® companion diagnostics for personalized c...

2023-12-06 07:22:53 ET DENVER, Colo., Dec. 6, 2023 ( www.247marketnews.com )- The following companies published announcements or traded higher on higher-than-usual volume; Siyata Mobile (NASDAQ: SYTA), Incannex Healthcare Inc (NASDAQ: IXHL), Yoshiharu Global Co. (NASDAQ: YOSH), Allarity...

2023-12-05 09:55:33 ET DENVER, Colo., Dec. 5, 2023 ( www.247marketnews.com )- The following companies published announcements or are trading higher on higher-than-usual volume; Allarity Therapeutics Inc (NASDAQ: ALLR), Clearmind Medicine Inc (NASDAQ: CMND), Harbor Custom Development Inc...

2023-12-05 09:17:19 ET More on Allarity Therapeutics Seeking Alpha’s Quant Rating on Allarity Therapeutics Historical earnings data for Allarity Therapeutics Financial information for Allarity Therapeutics For further details see: Allarity stock so...

2023-12-05 08:49:20 ET DENVER, Colo., Dec 5, 2023 ( www.247marketnews.com )- Allarity Therapeutics, Inc. (NASDAQ: ALLR) reported, this morning, hopeful initial results from its ongoing Phase 2 clinical trial evaluating the efficacy of its PARP inhibitor, stenoparib, in women w...

All evaluable participants, with prior PARP inhibitor therapy and chemotherapy, showed significant tumor shrinkage including one complete response Early data follows Phase 2 dose optimization change from once-daily to twice-daily Boston (December 5, 2023) — ...

INVO BioScience Inc. (INVO) is expected to report for Q3 2023 HIVE Blockchain Technologies Ltd (HIVE) is expected to report $-0.13 for Q2 2024 BioNexus Gene Lab Corp (BGLC) is expected to report for Q1 2024 Adhera Therapeutics Inc (ATRX) is expected to report for Q1 2024 Altus Pow...

Allarity Therapeutics Inc. (ALLR) is expected to report for Q3 2023

2023-11-02 17:24:45 ET More on Allarity Therapeutics Seeking Alpha’s Quant Rating on Allarity Therapeutics Historical earnings data for Allarity Therapeutics Financial information for Allarity Therapeutics For further details see: Allarity Therapeu...